Adamas Announces Pricing of Public Offering of Common Stock

EMERYVILLE, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the pricing of its underwritten public offering of 2,500,000 shares of its common stock at a price to the public of $23.00 per share. Adamas also granted the underwriters a 30-day option to acquire an additional 375,000 shares from Adamas. The offering is expected to close on January 12, 2016, subject to customary closing conditions.

Cowen and Company, LLC and Piper Jaffray & Co. are acting as book-running managers for the proposed offering, with William Blair & Company, L.L.C., JMP Securities LLC and Trout Capital LLC acting as co-managers.

A shelf registration statement relating to the shares was filed with the Securities and Exchange Commission on May 18, 2015 and became effective on June 1, 2015. The offering will be made only by means of a prospectus supplement. When available, copies of the prospectus supplement and accompanying prospectus relating to the public offering may be obtained by contacting Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, Telephone: 631-274-2806, Fax: 631-254-7140; or Piper Jaffray & Co., 800 Nicollet Mall, Suite 1000, Minneapolis, MN 55402, Telephone: 800-747-3924, Email: [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc. is a biopharmaceutical company committed to developing product candidates for the treatment of chronic disorders of the central nervous system.

Forward-Looking Statements

This announcement contains forward-looking statements, including statements relating to Adamas’ expectations regarding the completion of the proposed public offering. These statements are subject to significant risks and uncertainties, actual results could differ materially from those projected and Adamas cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the public offering. There can be no assurance that Adamas will be able to complete the public offering on the anticipated terms, or at all. Risks and uncertainties relating to Adamas and its business can be found in the “Risk Factors” section of Adamas’ Form 10-Q, filed with the SEC on November 12, 2015, and in the preliminary prospectus supplement related to the proposed offering filed with the SEC on January 5, 2016. Adamas undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in Adamas’ expectations.

For questions, please contact:
Julie Wood
Corporate Communications & Investor Relations
Adamas Pharmaceuticals, Inc. 
Phone: 510-450-3528